Home/Filings/4/0001725160-23-000016
4//SEC Filing

Paul Andrea 4

Accession 0001725160-23-000016

CIK 0001725160other

Filed

Jan 31, 7:00 PM ET

Accepted

Feb 1, 7:06 PM ET

Size

7.1 KB

Accession

0001725160-23-000016

Insider Transaction Report

Form 4
Period: 2023-02-01
Paul Andrea
Chief Legal Officer
Transactions
  • Award

    Common Stock

    2023-02-01+40,78340,783 total
  • Award

    Stock Option (Right to Buy)

    2023-02-01+59,21759,217 total
    Exercise: $23.65Exp: 2033-01-31Common Stock (59,217 underlying)
Footnotes (2)
  • [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
  • [F2]The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.

Issuer

Zentalis Pharmaceuticals, Inc.

CIK 0001725160

Entity typeother

Related Parties

1
  • filerCIK 0001863130

Filing Metadata

Form type
4
Filed
Jan 31, 7:00 PM ET
Accepted
Feb 1, 7:06 PM ET
Size
7.1 KB